Support The Moscow Times!

Putin Urges BRICS to Mass Produce Russian Covid-19 Vaccines

Russia is part of the BRICS alliance of major emerging countries. Kremlin.ru

Russian President Vladimir Putin on Tuesday called on fellow members of the BRICS alliance of major emerging countries to mass produce Russian-made coronavirus vaccines. 

Speaking during an online summit of Brazil, Russia, India, China and South Africa, Putin encouraged the other four BRICS members to manufacture and distribute coronavirus vaccines developed by Russia. 

"There are Russian vaccines, they work, they work effectively and safely... It's very important to unite for the mass production of these products into wide circulation," Putin said.

Putin noted that Russia has agreements in place with India and Brazil to conduct clinical trials of its Sputnik V coronavirus vaccine, as well as manufacturing agreements with China and India.

The world's largest vaccine producer is in India, the Serum Institute of India.

The Russian leader did not offer specifics as to what broader efforts between the five countries to mass produce the vaccines would entail, or outline the commercial conditions.

Russia has registered two coronavirus vaccines as a global race heats up in producing an effective vaccine to combat the pandemic, which has now claimed the lives of 1.3 million people.

In August, Russia announced that it had registered the world's first Covid-19 vaccine, Sputnik V named after the Soviet-era satellite but did so ahead of large-scale clinical trials.

Last month, Putin announced that Russia had registered a second coronavirus vaccine, EpiVacCorona. 

Russia has applied to the World Health Organization for accelerated registration and pre-qualification of the Sputnik V vaccine, which Russia has said is 92% effective. 

Some Western scientists have expressed concern over the vaccine, warning that moving too quickly could be dangerous.

Pharma giants Pfizer and BioNTech earlier this month announced that their virus vaccine is 90% effective, while U.S. company Moderna said Monday early results showed its candidate was 94.5% effective.

Sign up for our free weekly newsletter

Our weekly newsletter contains a hand-picked selection of news, features, analysis and more from The Moscow Times. You will receive it in your mailbox every Friday. Never miss the latest news from Russia. Preview
Subscribers agree to the Privacy Policy

A Message from The Moscow Times:

Dear readers,

We are facing unprecedented challenges. Russia's Prosecutor General's Office has designated The Moscow Times as an "undesirable" organization, criminalizing our work and putting our staff at risk of prosecution. This follows our earlier unjust labeling as a "foreign agent."

These actions are direct attempts to silence independent journalism in Russia. The authorities claim our work "discredits the decisions of the Russian leadership." We see things differently: we strive to provide accurate, unbiased reporting on Russia.

We, the journalists of The Moscow Times, refuse to be silenced. But to continue our work, we need your help.

Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $2. It's quick to set up, and every contribution makes a significant impact.

By supporting The Moscow Times, you're defending open, independent journalism in the face of repression. Thank you for standing with us.

Once
Monthly
Annual
Continue
paiment methods
Not ready to support today?
Remind me later.

Read more